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S U M M A R Y
Objectives: This study was performed to determine the local etiologic pattern of blood culture isolates
and antibiotic resistance in febrile neutropenic patients with hematological malignancies.
Methods: A total of 142 blood culture isolates from febrile neutropenic patients admitted to our
hematology unit were examined, particularly for the detection of cefepime resistance, because cefepime,
a fourth-generation cephalosporin, has been used in our unit as initial therapy for febrile neutropenia.
Results: Among all isolates, 67 (47.2%) were Gram-positive bacteria, the majority of which were fully
sensitive to vancomycin. Gram-negative bacteria accounted for 68 (47.9%) of the isolates. Cefepime
resistance was seen in 24 (35.3%) of the Gram-negative isolates, and had signiﬁcantly increased in 2007.
The cefepime-resistant isolates primarily consisted of Escherichia coli, Pseudomonas aeruginosa, and
Klebsiella pneumoniae. Approximately 60% of the cefepime-resistant isolateswere extended-spectrumb-
lactamase (ESBL)-producing organisms. Molecular analysis showed the predominant emergence of CTX-
M types. Most of the cefepime-resistant isolates were resistant to third- and various fourth-generation
cephalosporins, while having a high susceptibility to carbapenems, particularly meropenem.
Conclusions: Cefepime resistance was often detected in the blood culture isolates from febrile
neutropenic patients. This result suggests that therapeutic strategies for febrile neutropenia should be
modiﬁed based on the local antibiotic resistance patterns.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Bacteremia is clinically seen in febrile neutropenic patients
with hematological malignancies. In particular, Gram-negative
organisms are renowned for inducing septic shock, which is often
followed by sepsis-related death. Several groups have reported
that the prevalence of Gram-negative bacteremia has increased
among episodes of febrile neutropenia in hemato-oncology
units.1,2
A prompt initiation of empirical antibiotic therapy is favorable
for patients with febrile neutropenia, regardless of the detection of
bacteremia. Many clinical studies have recommended broad-
spectrum antibiotics covering both Gram-positive and–negative
bacteria as ﬁrst-line treatment for febrile neutropenic patients.
Certain speciﬁc agents have been used worldwide, including third-
and fourth-generation cephalosporins, carbapenems, and b-
lactam/b-lactamase inhibitor combinations. In recent years,* Corresponding author. Fukuoka, Japan. Tel.: +81 92 291 3434;
fax: +81 92 291 3266.
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be comparable to combination therapy with regard to the efﬁcacy
of treatment of febrile neutropenia.3–6 Based on these studies and
guidelines,7,8 our unit adopted the single administration of
cefepime, a fourth-generation cephalosporin, as the initial
treatment for febrile episodes in neutropenic patients.
It is now unquestioned that the use of broad-spectrum
antimicrobial agents renders many clinically important organisms
highly resistant to various antibiotics. In the general population,
extended-spectrumb-lactamase (ESBL)-producing Gram-negative
bacteria have been reported to be increasing in prevalence among
all bacteria detected, and an increase in the use of cephalosporins
may be related to the emergence of ESBL-producing bacteria.9,10 In
febrile neutropenic patients with hematological malignancies, the
relatively recent resistance pattern of Gram-negative bacteremia
appears inconclusive. Commonly used agents, such as cefepime
and carbapenems, have shownhigh activity against Gram-negative
bacteremia detected in neutropenic patients,11 while other studies
have reported the occurrence of Gram-negative bacteremia
resistant to many antibiotics.12–14 The susceptibility pattern of
organisms isolated from one region may not be the same as that
found in other regions of the world, as various environmentalses. Published by Elsevier Ltd. All rights reserved.
Table 1
Etiologic agents isolated from febrile neutropenic patients with bacteremia
Organism No. of isolates %
Gram-negative
Escherichia coli 26 18.3
Pseudomonas aeruginosa 21 14.8
Klebsiella pneumoniae 13 9.2
Enterobacter species 5 3.5
Other 3 2.1
Gram-negative, total 68 47.9
Gram-positive
Staphylococcus species, total 47 33.1
Coagulase-negative staphylococci 46 32.4
Staphylococcus aureus 1 0.7
Streptococcus species, total 9 6.3
a-Hemolytic streptococci 6 4.2
Other 3 2.1
Enterococcus species 8 5.6
Other 3 2.1
Gram-positive, total 67 47.2
Other 7 4.9
Isolates, total 142 100
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constant surveillance and reporting are needed regarding antibi-
otic susceptibility. This is particularly important in the ﬁeld of
febrile neutropenic bacteremia, because the emergence of isolates
resistant to critical antibiotics limits antibiotic choices and may
lead to an increase in infection-related mortality.
In this study, 142 blood culture isolates recovered from febrile
neutropenic patients treated in a single hematological unit were
analyzed with regard to etiology and susceptibility to antibiotics.
Cefepime resistance was seen in 24 (35.3%) of 68 Gram-negative
isolates. Approximately 60% of the cefepime-resistant isolates
were ESBL-producing Escherichia coli and Klebsiella pneumoniae.
Moreover, molecular characterization of ESBL-producing isolates
showed a predominance of the CTX-M-type, which is currently
emerging worldwide. Although these results were obtained from a
single institution, they contain important information that implies




A total of 872 patients were admitted to the blood and marrow
transplantation unit at Hara-Sanshin Hospital from January 2006
to December 2008. Bacteremia in febrile neutropenic patients was
analyzed in the present study for two reasons: (1) the number of
Gram-negative strains isolated up to the year 2005was very small,
and (2) some of the patients admitted up until 2005 had received
prophylactic administration of antibiotics during neutropenic
periods. The prophylactic use of antibiotics is known to affect
the etiology of febrile neutropenic bacteremia.15 Neutropenic
patients admitted after January 2006 had only taken antimycotic
agents for prophylaxis.
All the patients with febrile neutropenia were registered and
their informed consent for study participation was obtained.
Febrile neutropenia was deﬁned as a neutrophil count
of < 0.5  109 cells/l and an axillary temperature of > 38.0 8C.
Cefepime, a fourth-generation cephalosporin, has been adopted as
an initial empirical antibiotic agent for febrile neutropenic
patients. Cefepime at a dosage of 4 g/day was used, and during
the study period the deﬁned daily dose per 1000-patient days of
cefepimewas 171. The administration of antibiotics was continued
until recovery of neutrophil counts and/or resolution of infection.
When bacteria were isolated from a blood culture, antimicrobial
therapy was adjusted according to the antibiotic resistance
patterns obtained.
Detailed information on patients was collected from computer
databases. These data included age, sex, malignant disease
classiﬁcation, presence of indwelling catheter, neutrophil counts,
prior antibiotic usage, and clinical outcome. Information on
isolated strains, including etiology and susceptibility to antibiotics,
was obtained from a microbiology laboratory computer database.
2.2. Microbiology
In our unit, blood culture tests are conducted for all patients
with febrile neutropenia. An automated blood culture system
(BACTEC) was used for each test. Several samples were obtained
from the same patient and treated as independent results.
Antibiotic susceptibilities were determined by the breakpoints
standardized by the Clinical and Laboratory Standards Institute
(CLSI; formerly the NCCLS).16 The screening and conﬁrmation tests
for ESBL and metallo-b-lactamase were conducted according to
the recommendations of the CLSI.16 In addition, b-lactamase
producers were conﬁrmed using a Cica b test I/MBL kit (KantoChemical Co. Ltd, Tokyo, Japan). Strains that were positive for ESBL
based on the conﬁrmation tests were then evaluated for genotype.
The genotyping of metallo-b-lactamase was conducted when the
screening test was positive. PCR was conducted using ﬁve sets of
primers to amplify type-speciﬁc ESBL genes, including CTX-M,
TEM, and SHV types.17 Three sets of primers were used to detect
group-speciﬁc CTX-M b-lactamase genes, and then the different
types of CTX-M were determined by DNA sequencing.17 PCR was
conducted using primers speciﬁc for metallo-b-lactamase genes.
2.3. Statistical analysis
For the basic characteristics of patients with cefepime-resistant
isolates and patients with cefepime-sensitive isolates, categorical
variables were analyzed using a two-tailed Chi-square test, and
continuous variables were compared using the Mann–Whitney U-
test. Odds ratios and 95% conﬁdence intervals were calculated to
compare resistance patterns to various antibiotics between
cefepime-resistant and cefepime-sensitive isolates. A value of
p < 0.05was considered to be statistically signiﬁcant. All statistical
calculations were performed using SAS software (SAS Institute,
Inc., Cary, NC, USA).
3. Results
3.1. Cefepime-resistant Gram-negative bacteremia in febrile
neutropenic patients
A total of 142 bacteria were recovered from blood cultures
associated with 798 febrile episodes in patients with hematologi-
cal malignancies (Table 1). Among febrile episodes with bacter-
emia, 132 were caused by a single strain and ﬁve by two strains.
The incidence of Gram-positive isolates was approximately 50%,
with coagulase-negative staphylococci (CoNS) being predomi-
nant. Methicillin-resistant Staphylococcus aureus (MRSA) and
vancomycin-resistant Enterococcus (VRE) were not detected
among the Gram-positive isolates. Among the isolates, 68
(47.9%) were Gram-negative organisms, of which E. coli (18.3%),
P. aeruginosa (14.8%), and K. pneumoniae (9.2%) accounted for the
majority. We focused on Gram-negative isolates rather than
Gram-positive ones, because CoNS, which were predominant
among Gram-positive isolates, indicated the possibility of
contaminated samples; themajority of the Gram-positive isolates
were fully sensitive to vancomycin,which is addedwhen isolating
Gram-positive strains.
Table 2
Numbers of cefepime-resistant Gram-negative agents isolated from febrile neutropenic patients with bacteremia
Gram-negative, total Escherichia coli Pseudomonas aeruginosa Klebsiella pneumoniae
Year Total No. of
isolates















No. (%) of isolates
resistant to
cefepime
2003–2005 9 0 (0) 6 0 (0) 2 0 (0) 1 0 (0)
2006–2008 68 24 (35.3) 26 12 (46.2) 21 10 (47.6) 13 2 (15.4)
2006 20 2 (10) 8 0 (0) 6 2 (33.3) 3 0 (0)
2007 23 11 (47.8) 10 7 (70) 8 4 (50) 4 0 (0)
2008 25 11 (44) 8 5 (62.5) 7 4 (57.1) 6 2 (33.3)
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an antibiotic agent adopted at our institution as an initial therapy
for febrile neutropenia, was examined because a high rate of
resistance to cefepime affects the choice of empirical antibiotics for
febrile neutropenia. Table 2 shows the number of cefepime-
resistant Gram-negative strains isolated from febrile neutropenic
patients in each year of this study. Cefepime-resistant isolates
comprised 24 (35.3%) of 68 Gram-negative isolates analyzed, and
had signiﬁcantly increased in 2007. About half of the isolates of E.
coli and P. aeruginosa showed resistance to cefepime, and
approximately 20% of K. pneumoniae were resistant to cefepime.
3.2. Phenotypic and molecular characterization of cefepime-resistant
Gram-negative strains
The cefepime-resistant Gram-negative isolates were then
characterized with respect to production of b-lactamase
enzymes. Screening of strains producing ESBL and metallo-b-
lactamase was conducted. Four P. aeruginosa isolates were
suspected to be metallo-b-lactamase producers, but no strains
were conﬁrmed as metallo-b-lactamase producers using PCR
methods. All cefepime-resistant E. coli and K. pneumoniae strains
were phenotypically identiﬁed as ESBL-producing isolates by the
clavulanate test, and all were conﬁrmed as isolates containing
ESBL genes at amolecular level. Table 3 shows the ESBL genotypes
of all cefepime-resistant E. coli and K. pneumoniae strains. Twelve
cefepime-resistant E. coli isolates were classiﬁed as the following
four types: CTX-M-14 alone, a combination of CTX-M-14 and CTX-
M-2, a combination of CTX-M-14 and TEM, and TEM alone. Two K.
pneumoniae strains resistant to cefepimeproduced CTX-M-14 and
SHV b-lactamase. Although there is concern over the spread of a
particular ESBL strain through nosocomial outbreaks, the detec-
tion of different ESBL genotypes indicates that these ESBL-
producing strains did not disseminate from a single strain with a
certain genotype.Table 3
Genotypic detection of ESBL-producing agents isolated from febrile neutropenic
patients with bacteremia
Case Organism CTX-M type TEM type SHV type
1 Escherichia coli CTX-M-14
2 Escherichia coli CTX-M-14
3 Escherichia coli CTX-M-14
4 Escherichia coli CTX-M-14
5 Escherichia coli CTX-M-14
6 Escherichia coli CTX-M-14
7 Escherichia coli CTX-M-14 CTX-M-2
8 Escherichia coli CTX-M-14 TEM
9 Escherichia coli CTX-M-14 TEM
10 Escherichia coli CTX-M-14 TEM
11 Escherichia coli TEM
12 Escherichia coli TEM
13 Klebsiella pneumoniae CTX-M-14 SHV
14 Klebsiella pneumoniae CTX-M-14 SHV3.3. Antimicrobial susceptibilities of cefepime-resistant Gram-
negative strains
Table 4 shows the resistance rates to different antibiotics of
cefepime-resistant, ESBL-producing, and cefepime-sensitive iso-
lates. Most of the cefepime-resistant and ESBL-producing isolates
were resistant to all generations of cephalosporins, and this
resistance pattern was signiﬁcantly different to that of cefepime-
sensitive isolates. Most cefepime-resistant isolates were resistant
to various fourth-generation cephalosporins, such as cefozopran
and cefpirome. In contrast, most cefepime-resistant isolates
retained favorable susceptibility to carbapenems, and only
approximately 10% of cefepime-resistant isolates were resistant
to meropenem. All ESBL-producing isolates were sensitive to
carbapenems. Most of the cefepime-resistant and ESBL-producing
isolates were susceptible to aminoglycosides.
Serial blood cultures were acquired for 20 of 24 patients (83.3%)
with cefepime-resistant, 12 of 14 patients (85.7%) with ESBL-
producing, and 39 of 44 patients (88.6%) with cefepime-sensitive
bacteremia. The detected bacteria were eliminated after antibiotic
treatment in all of the groups. In the control patients with
cefepime-sensitive bacteremia, no patients died of infection during
antibiotic therapy. In case patients with cefepime-resistant
bacteremia, one patient died during treatment, due to possible
septic shock caused by P. aeruginosa. This P. aeruginosa isolate was
resistant to carbapenems, including imipenem/cilastatin and
meropenem. There were no mortalities among patients with
ESBL-producing bacteremia during antimicrobial therapy.
4. Discussion
The present study results indicate an increase in cefepime-
resistant Gram-negative bacteremia in febrile neutropenic
patients with hematological malignancies under the therapeutic
strategy of cefepime usage as an initial antibiotic treatment.
Cefepime-resistant isolates consisted of P. aeruginosa, E. coli, and K.
pneumoniae. None of the P. aeruginosa strains producedmetallo-b-
lactamase, while all of the E. coli and K. pneumoniae strains were
ESBL producers. Furthermore, genotyping of the ESBL enzymes
indicated the predominance of the CTX-M type. To our knowledge,
no previous reports have described the molecular analysis of b-
lactamase in the ﬁeld of bacteremia recovered from febrile
neutropenic patients. These data give rise to practical suggestions
for surveillance and therapeutic strategies.
The present study indicated that CTX-M enzymes are most
prevalent in ESBL-producing strains isolated from febrile neutro-
penic bacteremia. Recent surveillance tests have reported that
organisms producing CTX-M b-lactamase, a new ESBL type, have
been replacing those that produce TEM and SHV enzymes, the
original ESBL types.18,19 CTX-M-producing bacteria acquire resis-
tance to all generations of cephalosporins, while remaining highly
susceptible to carbapenems.19 The present data are consistentwith
this resistance pattern of organisms with CTX-M ESBL enzymes. As
a characteristic of the CTX-M type, CTX-M-producing bacteria not
Table 4
Resistance pattern to different antibiotics in cefepime-resistant, ESBL-producing, and cefepime-sensitive isolates
Antibiotic Cefepime-resistant (n=24) ESBL-producing (n=14) Cefepime-sensitive (n=44) p-Valuea
b-lactams
Penicillins (e.g., piperacillin) 23 (95.8) 13 (92.9) 14 (31.8) <0.0001
Cephems
1st-generation cephems (e.g., cefazolin) 24 (100) 14 (100) 2 (4.5) <0.0001
2nd-generation cephems (e.g., cefotiam) 24 (100) 14 (100) 1 (2.3) <0.0001
3rd-generation cephems (e.g., cefotaxime) 22 (91.7) 12 (85.7) 2 (4.5) <0.0001
4th-generation cephems (e.g., cefpirome) 23 (95.8) 13 (92.9) 2 (4.5) <0.0001
Carbapenems
Imipenem/cilastatin 4 (16.7) 0 (0) 2 (4.5) 0.09
Meropenem 2 (8.3) 0 (0) 2 (4.5) 0.5
Monobactams (e.g., aztreonam) 24 (100) 14 (100) 5 (11.4) <0.0001
Aminoglycosides (e.g., amikacin) 3 (12.5) 1 (7.1) 1 (2.3) 0.09
Tetracyclines (e.g., minocycline) 7 (29.2) 4 (28.6) 9 (20.4) 0.4
Data are n (%) of isolates.
a p-Value shows statistical comparison for each antibiotic between 24 cefepime-resistant isolates and 44 cefepime-sensitive isolates.
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spreading throughout community environments.19 Also, it should
be considered that CTX-M ESBL-producing organisms could be
imported from a community site. To identify community-onset
nosocomial infections induced by CTX-M-producing organisms,
surveillance for ESBL genotyping and cloning is needed in all units,
not just hematology units.
It would be reasonable to assume that Gram-negative bacter-
emia caused by febrile neutropenia could induce fatal infections,
and that failure of an initial treatment for multidrug-resistant
bacteremia might lead to a highmortality. However, in the present
study, only one patient died during treatment of Gram-negative
bacteremia, both cefepime-sensitive and cefepime-resistant. In
most cases of patients with cefepime-resistant isolates, rapid
bacterial detection and prompt antibiotic change resulted in
successful treatment. All of the secondary antibiotics, except in
two cases, were meropenem, and this treatment success clinically
reinforces the ﬁnding that approximately 90% of the cefepime-
resistant strains, including ESBL-producers, were sensitive to
meropenem. The clinical outcome of infections caused by ESBL-
producing organisms remains controversial, because no prospec-
tive studies have been conducted to assess prognosis in a
statistically signiﬁcant number of patients.9 All observations,
including the present data, have been obtained from case–control
studies with relatively small numbers of patients.9 A new study
should be designed to speciﬁcally resolve this clinical question.
Our unit has faced an increase in bacteremia resistant to
cefepime, which has been used as an initial antibiotic agent for
febrile neutropenia, while carbapenems, especially meropenem,
retain high activity against cefepime-resistant bacteremia. Al-
though it appears reasonable to choose carbapenems as the initial
antimicrobial treatment for patients with febrile neutropenia, this
treatment would be adopted only in the case of our patients. The
use of high doses of carbapenems may result in the emergence of
multidrug-resistant P. aeruginosa strains, which have been less
frequently detected in our unit. In recent years, many comparative
studies have recommended carbapenems and b-lactam/b-lacta-
mase inhibitor combinations, particularly piperacillin–tazobac-
tam, as an initial therapy for febrile neutropenia.5,6 Rotation of
antibiotics has been suggested as a strategy to control the
resistance of microorganisms to antibiotic treatments. Bacteria
that are resistant to one class of antibiotics would be eliminated by
another class of antibiotics, which results in their growth
inhibition. For febrile neutropenic patients, our unit has instituted
rotation of the primary antimicrobial, including cefepime, mer-
openem, and piperacillin–tazobactam. The primary purpose is to
evaluate whether rotation of antibiotics affects the susceptibilitypatterns of multidrug-resistant bacteremia in febrile neutropenic
patients.
One concern is that failure of the ﬁrst antibiotic therapy for
febrile neutropenic patients may inﬂuence mortality. The present
data reinforce the need for continuous surveillance, including
etiology and resistance patterns; this is indispensable in choosing
appropriate antibiotics for febrile neutropenic bacteremia. More-
over, the present study identiﬁed a high prevalence of multidrug-
resistant organisms with CTX-M ESBL types, which are currently
on the increase worldwide. Identiﬁcation of the genotypes of b-
lactamase-producing organisms provides valuable information on
antibiotic resistance patterns.
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